Skip to content

Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis

Hep C quad regimens quashed, but some components go forward

Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care

A majority of HIV-positive gay men in Dutch survey take their viral load into consideration if having unprotected sex

Researchers stop the only current HIV vaccine efficacy trial

AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1

AbbVie interferon-free combination cures over 90% of hepatitis C genotype 1

Sofosbuvir + ribavirin cures most genotype 2 hepatitis C, but genotype 3 response is lower

Sofosbuvir + ribavirin cures most genotype 2 hepatitis C, but genotype 3 response is lower

Consistent decline in partner numbers in US gay men in last decade, but no change in condom use

Genetics make a large contribution to cardiovascular risk for people with HIV